Asian age-related macular degeneration phenotyping study: Rationale, design and protocol of a prospective cohort study

Clinical and Experimental Ophthalmology

Volumn 40, Issue 7, 2012, Pages 727-735

  Cheung, Chui Ming G ^a,b   Bhargava, Mayuri ^a,b,c   Laude, Augustinus ^b,d   Koh, Adrian Ch ^b,e   Xiang, Li ^b   Wong, Doric ^a   Niang, Thet ^c   Lim, Tock Han ^d   Gopal, Lingam ^b,c   Wong, Tien Y ^a,b,c,f  

^a SINGAPORE NATIONAL EYE CENTRE   (Singapore)

^b SINGAPORE EYE RESEARCH INSTITUTE   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d TAN TOCK SENG HOSPITAL   (Singapore)

^e Camden Medical Centre   (Singapore)

^f UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Age related macular degeneration (AMD); Epidemiology; Retina

Indexed keywords

ARTICLE; ASIAN; HUMAN; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PHENOTYPE; PROSPECTIVE STUDY; RETINA MACULA AGE RELATED DEGENERATION; STUDY DESIGN;

ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; CLINICAL PROTOCOLS; COHORT STUDIES; DATABASES, FACTUAL; FLUORESCEIN ANGIOGRAPHY; HUMANS; INDIA; INTRAOCULAR PRESSURE; MACULAR DEGENERATION; PHENOTYPE; PROSPECTIVE STUDIES; RESEARCH DESIGN; RISK FACTORS; SINGAPORE; TOMOGRAPHY, OPTICAL COHERENCE;

EID: 84867403686     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/j.1442-9071.2012.02765.x     Document Type: Article

References (38)

1. Wong TY, Loon SC, Saw SM. The epidemiology of age related eye diseases in Asia. Br J Ophthalmol 2006; 90: 506-11.
2. Klein R, Klein BE, Knudtson MD etal. Prevalence of age related macular degeneration in 4 racial/ethnic groups in the Multi-Ethnic Study of Atherosclerosis. Ophthalmology 2006; 113: 373-80.
3. Mitchell P, Smith W, Attebo K, Wang JJ. Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study. Ophthalmology 1995; 102: 1450-60.
4. Kawasaki R, Yasuda M, Song SJ etal. The prevalence of age-related macular degeneration in Asians. Ophthalmology 2010; 117: 921-7.
5. Rosenfeld PJ, Brown DM, Heier JS etal. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-31.
6. Brown DM, Kaiser PK, Michels M etal. Ranibizumab versus verteportin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432-44.
7. The CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364: 1897-908.
8. Haines JL, Hauser MA, Schmidt S etal. Complement factor H variant increases the risk of age-related macular degeneration. Science 2005; 308: 419-21.
9. Klein RJ, Zeiss C, Che EY etal. Complement factor H polymorphism in age-related macular degeneration. Science 2005; 308: 385-9.
10. Edwards AO, Ritter R III, Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement factor H polymorphism and age-related macular degeneration. Science 2005; 308: 421-4.
11. The Age-Related Eye Disease Research Group. The Age-Related Eye Disease Study (AREDS): risk factors associated with age-related macular degeneration. AREDS Report No. 3. Ophthalmology 2000; 107: 2224-32.
12. Wong T, Chakravarthy U, Klein R etal. The natural history and prognosis of neovascular age-related macular degeneration. A systematic review of the literature and meta-analysis. Ophthalmology 2008; 115: 116-26.
13. Chakravarthy U, Wong TY, Fletcher A etal. Clinical risk factors for age-related macular degeneration: a systemic review and meta-analysis. BMC Ophthalmol 2010; 10: 31-43.
14. Kawasaki R, Wang JJ, Aung T etal. Prevalence of age-related macular degeneration in a Malay population: the Singapore Malay Eye Study. Ophthalmology 2008; 115: 1735-41.
15. Laude A, Cackett PD, Vithana EN etal. Polypoidal choroidal vasculopathy and neovascular age-related macular degeneration: same or different disease? Prog Retin Eye Res 2010; 29: 19-29.
16. Lim TH, Laude A, Tan CSH. Polypoidal choroidal vasculopathy: an angiographic discussion. Eye 2010; 24: 483-90.
17. Uyama M, Wada M, Nagai Y etal. Polypoidal choroidal vasculopathy: natural history. Am J Ophthalmol 2002; 133: 639-48.
18. Maruko I, Iida T, Saito M etal. Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol 2007; 144: 15-22.
19. Chan WM, Lam DS, Lai TY etal. Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy one-year results of a prospective case series. Ophthalmology 2004; 111: 1576-84.
20. Gomi F, Ohji M, Sayanagi K etal. One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients. Ophthalmology 2008; 115: 141-6.
21. Kurashige Y, Otani A, Sasahara M etal. Two-year results of photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 2008; 146: 513-19.
22. Gomi F, Sawa M, Sakaguchi H etal. Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy. Br J Ophthalmol 2008; 92: 70-3.
23. Lai TY, Chan WM, Liu DT, Luk FO, Lam DS. Intravitreal bevacizumab (Avastin) with or without photodynamic therapy for the treatment of polypoidal choroidal vasclopathy. Br J Ophthalmol 2008; 92: 661-6.
24. Lai TY. The EVEREST study group. Verteporfin PDT and ranibizumab combination therapy for symptomatic macular polypoidal choroidal vasculopathy (PCV): EVEREST results. Invest Ophthalmol Vis Sci 2010; 51 (Suppl.): S2228.
25. Ministry of Health. National Health Survey. 2004. Singapore. Accessed 15 February 2012. Available from: http://www.singstat.gov.sg/pubn/papers/people/ssnsep05-pg19-20.pdf.
26. Foong AWP, Saw SM, Loo JL etal. Rationale and methodology for a population-based study of eye diseases in Malay people: the Singapore Malay Eye Study (SiMES). Ophthalmic Epidemiol 2007; 14: 25-35.
27. Lavanya R, Jeganathan VSE, Zheng Y etal. Methodology of the Singapore Indian Chinese cohort (SICC) eye study: quantifying ethnic variations in the epidemiology of eye diseases in Asians. Ophthalmic Epidemiol 2009; 16: 325-36.
28. Diabetic Retinopathy Study Coordinating Center. Diabetic Retinopathy Study: Manual of Operations. Baltimore, MD: Diabetic Retinopathy Study Coordinating Center, 1972.
29. Saw SM, Foster PJ, Gazzard G, Seah S. Causes of blindness, low vision, and questionnaire-assessed poor visual function in Singaporean Chinese adults: the Tanjong Pagar Survey. Ophthalmology 2004; 111: 1161-8.
30. Lamoureux EL, Chong EW, Thumboo J etal. V impairment, ocular conditions, and vision-specific function: the Singapore Malay Eye Study. Ophthalmology 2008; 115: 1973-81.
31. Lamoreux EL, Mitchell P, Rees G etal. Impact of early and late age-related macular degeneration on vision-specific functioning. Br J Ophthalmol 2011; 95: 666-70.
32. Klein R, Davis MD, Magli YL etal. The Wisconsin age-related maculopathy grading system. Ophthalmology 1991; 98: 1128-34.
33. Cheung CM, Cheung CY, Yang EL, Mitchell P, Wang JJ, Wong TY. Retinal arteriolar wall signs and early age-related macular degeneration: the Singapore Malay Eye Study. Am J Ophthalmol 2011; 152: 108-13.
34. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol 1991; 109: 1219-30.
35. Japanese Study Group of Polypoidal Choroidal Vasculopathy. Criteria for diagnosis of polypoidal choroidal vasculopathy. Nippon Ganka Gakkai Zasshi 2005; 109: 417-27 [in Japanese].
36. Tsujikawa A, Ojima Y, Yamashiro K etal. Development of polypoidal lesions in age-related macular degeneration. Eye 2011; 25: 481-8.
37. Lee MW, Yeo I, Wong D, Ang CL. Argon laser photocoagulation for the treatment of polypoidal choroidal vasculopathy. Eye 2009; 23: 145-8.
38. Kwok AK, Lai TY, Chan CW, Neoh EL, Lam DS. Polypoidal choroidal vasculopathy in Chinese patients. Br J Ophthalmol 2002; 86: 892-7.